Table 1.

Characteristics of patients with infective endocarditis

	N = 34
Age, median (IQR)	73 (63–81)
Male, n (%)	25 (73.5)
Charlson index, n (%)	2 (1–4)
Type of infection, n (%)
Definite IE	31 (91.2)
Probable IE	3 (8.8)
Endocarditis, n (%)
Native	11 (32.4)
Early prosthetic	5 (14.7)
Late prosthetic	10 (29.4)
Pacemaker lead	8 (23.5)
Valve affected, n (%)
Aortic	17 (50)
Mitral	8 (23.5)
Tricuspid	1 (2.9)
Causative organism, n (%)
MSSA	7 (20)
MRSA	3 (8.6)
CNS	15 (42.9)
E. faecalis	3 (8.6)
Streptococcus spp.	7 (20)
Patient received prior antibiotic therapy, n (%)	34 (100)
Days of previous antibiotic treatment, median (IQR)	28 (17–35)
Prior antibiotic therapy, n (%)
Daptomycin	24 (68.6)
Ceftriaxone	10 (28.6)
Linezolid	3 (8.6)
Vancomycin	8 (22.9)
Surgery, n (%)	12 (34.3)
Surgery before administering DBV	11 (91.6)
Reason for DBV administration, n (%)
Facilitate discharge	30 (88.6)
Prior treatment failure	3 (8.6)
DBV dose, n (%)
1000 mg (1 day), 500 mg (8 days)	10 (29.4)
1000 mg 1 day	5 (14.7)
1500 mg (1 day)	12 (35.3)
1000 mg (1 day), 500 mg (8 days), 500 mg (15 days)	1 (2.9)
1500 mg (1 day), 1000 mg (15 days)	3 (.8)
1500 mg (1 day), 1000 mg (15 days, 30 days, 45 days)	1 (2.9)
1000 mg (1 days), 500 mg every week/9 weeks	1 (2.9)
1500 mg (1 days), 1000 mg every 2 weeks/10 weeks	1 (2.9)
DBV-covered days, median (IQR)	14 (14–21)
Clinical cure, n (%)	34 (100)
Microbiological cure, n (%)	33 (97.1)
Follow-up blood cultures:	17 (48.6)
Negative follow-up blood cultures	17 (100)
IE-related death, n (%)
During hospitalisation	0
At 12 months	0
Relapse, n (%)	0
Median reduction in hospital stay (IQR)	14 (7–17)
Total reduction, days	557

MSSA methicillin-sensitive S. aureus; MRSA methicillin-resistant S. aureus, CNS coagulase-negative staphylococcus